AVITA Medical Reports Full-Year 2025 Results with Going Concern Warning, Details Debt Refinancing & Equity Raise

summarizeSummary

AVITA Medical's 2025 annual report includes a 'going concern' warning, despite securing a new $60M credit facility and completing a $14.8M equity raise, alongside reduced losses and 11% revenue growth.

check_boxKey Events

• Going Concern Warning Issued

  Management and auditors disclosed 'substantial doubt' about the company's ability to continue as a going concern due to debt obligations, historical negative cash flows, and recurring losses.

• New $60M Senior Secured Credit Facility

  On January 13, 2026, the company secured a new five-year senior secured credit facility of up to $60 million from Perceptive Advisors, with $50 million initially funded, replacing previous debt. Net proceeds from the refinancing were $6.0 million.

• Equity Private Placement Completed

  In August 2025, AVITA Medical completed a private placement on the ASX, raising $14.8 million (gross) through the issuance of 3,440,377 shares (equivalent to 17,201,886 CDIs).

• Improved Financial Performance in 2025

  The company reported an 11% increase in total revenues to $71.6 million, a 21% reduction in net loss to $(48.6) million, and a 25% reduction in operating loss to $(42.5) million for the year ended December 31, 2025.

auto_awesomeAnalysis

AVITA Medical's annual report highlights a critical 'going concern' warning from management and auditors, indicating substantial doubt about the company's ability to continue operations. This serious financial disclosure is partially mitigated by recent financing activities, including a new $60 million senior secured credit facility and a $14.8 million equity private placement. While the company reduced its net and operating losses and achieved 11% revenue growth in 2025, its accumulated deficit remains significant, and net cash used in operations is still substantial. The new debt facility comes with revised, lower cash covenants, providing some immediate liquidity relief, but the underlying financial challenges persist. Investors should closely monitor the company's ability to achieve profitability and meet its new revenue covenants.